Plasma Therapy Market Size, Share, Opportunities, And Trends By Type (Pure Platelet-Rich Plasma, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin, Plasma Proteins), By Source (Autologous, Allogenic), By Application (Orthopedic, Chronic Infectious Diseases, Dermatology, Dentistry, Cardiac Muscle Injury, Nerve Injury, Others), By End-user (Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Academic & Research Institutes, Others), And By Geography - Forecasts From 2024 To 2029

  • Published : May 2024
  • Report Code : KSI061616873
  • Pages : 140

The use of plasma-derived goods or plasma-rich components for medicinal reasons is included in the plasma treatment market. Blood's liquid component, plasma, includes proteins and antibodies that are essential for several medical uses. Plasma exchange, intravenous immunoglobulin therapy, and plasma infusion are among the treatments for immunological deficiencies, autoimmune diseases, and specific neurological disorders that fall under the category of plasma therapy. The rising incidence of chronic illnesses, improvements in plasma processing methods, and growing regenerative medicine applications are the main factors propelling the market`s expansion.

Furthermore, convalescent plasma therapy has gained attention as a potential treatment for severe cases due to the COVID-19 pandemic. But obstacles including complicated regulations, safety worries, and supply chain limitations could prevent the market from growing. However, with continued research and development initiatives and rising infrastructure spending in the healthcare sector.

Market Drivers:

  • Rising chronic diseases are anticipated to boost the plasma therapy market.

The requirement for plasma treatment, a procedure that employs blood plasma-containing antibodies to treat an assortment of ailments, has expanded due to the expansion in chronic disorders/diseases. This industry is growing due to diseases like autoimmune disorders, cancer, and immunological deficits. The capacity of plasma treatment to improve patient results and successfully manage their symptoms has pulled in an incredible deal of intrigue from both patients and healthcare experts. Plasma treatment is becoming a more practical medical alternative with each new study and advancement, giving hope for the management and treatment of progressed chronic ailments.

  • Growing applications in regenerative medicine are expected to boost the plasma therapy market.

The increasing applications of plasma treatment in regenerative pharmaceutical medication are driving noteworthy market expansion. Plasma-derived products abundant in growth components and cytokines are being progressively utilized to fortify tissue repair, wound recuperating, and recovery in orthopedic medicines, wound care, and aesthetic methods. As regenerative medicine picks up force as a viable treatment alternative, the requirement and demand for plasma-based treatments proceed to rise.

With progressing advancements in plasma preparing procedures and expanding awareness of their restorative potential, plasma treatment is predicted to play an essential part in tending to the developing healthcare needs for tissue recovery and wound administration.

For illustration, an upgraded set of follow-ups comes about from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an exploratory gene therapy for people with modestly extreme to serious hemophilia, which was released in December 2021 by Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic pharmaceuticals company.

  • Technological advancements are anticipated to boost the plasma therapy market.

The market for plasma treatment is growing essentially much appreciated to technological advancements. Higher-quality plasma-derived products with predominant safety and efficacy profiles are being delivered as a result of advancements in plasma processing, such as superior fractionation methodologies and progressed purification procedures. Moreover, modern plasma-based treatments with custom-fitted mechanisms of activity for a range of therapeutic disorders are being made feasible by improvements in biotechnology and molecular biology.

In addition to augmenting the therapeutic potential of plasma therapy, these technological advancements facilitate the investigation of novel applications in precision and regenerative medicine, propelling market growth and providing auspicious treatment alternatives for patients with heterogeneous healthcare requirements. The Rika Plasma Donation System (Rika), created by Terumo Blood and Cell Technologies (Terumo BCT), a medical technology business, was approved by the Food and Drug Administration (FDA) in March 2022. Rika is an automated technology of the future that focuses on the experience of donors and staff at plasma centers.

Asia Pacific region is predicted to dominate the marketplace.

The market for plasma therapy is growing essentially within the Asia-Pacific region. The region's increasing population, rising chronic ailments incidences, and development happening in the healthcare system are a few of the components expanding the market in the years ahead. The industry of plasma therapy is extending as a result of patients' and healthcare professionals' rising awareness of plasma-derived medications. Moreover, Adoption rates are also being driven by improvements in plasma-preparing technology and the availability of cost-effective treatment choices in countries all through the region.

Convalescent plasma treatment has moreover created intrigue due to the COVID-19 widespread, which has propelled market growth. The Asia-Pacific plasma treatment market IS expected to flourish due to persistent R&D endeavors and expanding healthcare investments, offering individuals within the REGION superior treatment choices and improving their healthcare results.

In 2024, Takeda declared that it would construct a new plasma-derived therapy (PDT) production plant in Osaka, Japan, at a cost of about 100 billion yen. This is Takeda's biggest-ever investment in increasing its manufacturing capacity in Japan. The facility will be constructed with the newest automation and cutting-edge digital technology by the strictest global manufacturing requirements. It will be a completely integrated factory with cold storage facilities in addition to capabilities for breakdown, fractionation, purification, filling, and finishing.

Market Restraints:

  • Consistent and sustainable plasma supply can constrain the market for plasma therapy.

Making sure there is a steady and sustainable supply of plasma is a significant concern for the plasma therapy industry. Products made from plasma are in greater demand since they are being used in more medical procedures. However, a significant portion of plasma collection comes from voluntary donations, which might vary and result in shortages. For plasma factories, logistical issues may arise from regulatory regulations and safety standards for plasma collecting and processing. These supply chain problems must be resolved to successfully meet the rising demand for plasma therapy.

Market Developments:

  • December 2023- Global healthcare giant Grifols, a pioneer in the production of medications derived from plasma, announced a strategic partnership with Haier Group (Haier) to expand into the Chinese plasma market. In terms of innovation, Haier leads the world. The two businesses will look for ways to combine Haier's superior array of healthcare products with Grifols' industry-leading plasma and diagnostic competence. Grifols and Haier see widespread collaboration as a means of supporting China's expanding and evolving healthcare infrastructure.
  • April 2023- A multinational biotechnology company called Biogen, with headquarters in the United States, announced on April 25, 2023, that the FDA had approved QALSODY injection, dosed at 100 mg/15 mL to treat adult patients with amyotrophic lateral sclerosis (ALS) who have a mutation in the superoxide dismutase 1 (SOD1) gene. Because patients receiving QALSODY showed a decrease in plasma neurofilament light chain (NfL), this indication has been granted accelerated approval. 

Market Segmentation

Plasma Therapy Market is segmented and analyzed as below:

  • By Type
    • Pure Platelet-Rich Plasma
    • Leukocyte-Rich PRP
    • Pure Platelet-Rich Fibrin
    • Leukocyte-Rich Fibrin
    • Plasma Proteins
  • By Source
    • Autologous
    • Allogenic
  • By Application
    • Orthopedic
    • Chronic Infectious Diseases
    • Dermatology
    • Dentistry
    • Cardiac Muscle Injury
    • Nerve Injury
    • Others
  • By End-user
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies
    • Academic & Research Institutes
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. PLASMA THERAPY MARKET BY TYPE

5.1. Introduction

5.2. Pure Platelet-Rich Plasma

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.3. Leukocyte-Rich PRP

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.4. Pure Platelet-Rich Fibrin

5.4.1. Market Trends and Opportunities

5.4.2. Growth Prospects

5.5. Leukocyte-Rich Fibrin

5.5.1. Market Trends and Opportunities

5.5.2. Growth Prospects

5.6. Plasma Proteins

5.6.1. Market Trends and Opportunities

5.6.2. Growth Prospects

6. PLASMA THERAPY MARKET BY SOURCE 

6.1. Introduction

6.2. Autologous

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.3. Allogenic

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

7. PLASMA THERAPY MARKET BY APPLICATION

7.1. Introduction

7.2. Orthopedic

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.3. Chronic Infectious Diseases

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

7.4. Dermatology

7.4.1. Market Trends and Opportunities

7.4.2. Growth Prospects

7.5. Dentistry

7.5.1. Market Trends and Opportunities

7.5.2. Growth Prospects

7.6. Cardiac Muscle Injury

7.6.1. Market Trends and Opportunities

7.6.2. Growth Prospects

7.7. Nerve Injury

7.7.1. Market Trends and Opportunities

7.7.2. Growth Prospect

7.8. Others

7.8.1. Market Trends and Opportunities

7.8.2. Growth Prospects

8. PLASMA THERAPY MARKET BY END-USER

8.1. Introduction

8.2. Hospitals and Clinics

8.2.1. Market Trends and Opportunities

8.2.2. Growth Prospects

8.3. Pharmaceutical and Biotechnology Companies

8.3.1. Market Trends and Opportunities

8.3.2. Growth Prospects

8.4. Academic & Research Institutes

8.4.1. Market Trends and Opportunities

8.4.2. Growth Prospects

8.5. Others 

8.5.1. Market Trends and Opportunities

8.5.2. Growth Prospects

9. PLASMA THERAPY MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Type

9.2.2. By Source

9.2.3. By Application

9.2.4. By End-User

9.2.5. By Country

9.2.5.1. United States

9.2.5.1.1. Market Trends and Opportunities

9.2.5.1.2. Growth Prospects

9.2.5.2. Canada

9.2.5.2.1. Market Trends and Opportunities

9.2.5.2.2. Growth Prospects

9.2.5.3. Mexico

9.2.5.3.1. Market Trends and Opportunities

9.2.5.3.2. Growth Prospects

9.3. South America

9.3.1. By Type

9.3.2. By Source

9.3.3. By Application

9.3.4. By End-User

9.3.5. By Country 

9.3.5.1. Brazil

9.3.5.1.1. Market Trends and Opportunities

9.3.5.1.2. Growth Prospects

9.3.5.2. Argentina

9.3.5.2.1. Market Trends and Opportunities

9.3.5.2.2. Growth Prospects

9.3.5.3. Others

9.3.5.3.1. Market Trends and Opportunities

9.3.5.3.2. Growth Prospects

9.4. Europe

9.4.1. By Type

9.4.2. By Source

9.4.3. By Application

9.4.4. By End-User

9.4.5. By Country

9.4.5.1. United Kingdom

9.4.5.1.1. Market Trends and Opportunities

9.4.5.1.2. Growth Prospects

9.4.5.2. Germany

9.4.5.2.1. Market Trends and Opportunities

9.4.5.2.2. Growth Prospects

9.4.5.3. France

9.4.5.3.1. Market Trends and Opportunities

9.4.5.3.2. Growth Prospects

9.4.5.4. Italy

9.4.5.4.1. Market Trends and Opportunities

9.4.5.4.2. Growth Prospects

9.4.5.5. Spain

9.4.5.5.1. Market Trends and Opportunities

9.4.5.5.2. Growth Prospects

9.4.5.6. Others

9.4.5.6.1. Market Trends and Opportunities

9.4.5.6.2. Growth Prospects

9.5. Middle East and Africa

9.5.1. By Type

9.5.2. By Source

9.5.3. By Application

9.5.4. By End-User

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.1.1. Market Trends and Opportunities

9.5.5.1.2. Growth Prospects

9.5.5.2. UAE

9.5.5.2.1. Market Trends and Opportunities

9.5.5.2.2. Growth Prospects

9.5.5.3. Others

9.5.5.3.1. Market Trends and Opportunities

9.5.5.3.2. Growth Prospects

9.6. Asia Pacific

9.6.1. By Type

9.6.2. By Source

9.6.3. By Application

9.6.4. By End-User

9.6.5. By Country

9.6.5.1. Japan

9.6.5.1.1. Market Trends and Opportunities

9.6.5.1.2. Growth Prospects

9.6.5.2. China

9.6.5.2.1. Market Trends and Opportunities

9.6.5.2.2. Growth Prospects

9.6.5.3. India

9.6.5.3.1. Market Trends and Opportunities

9.6.5.3.2. Growth Prospects

9.6.5.4. South Korea

9.6.5.4.1. Market Trends and Opportunities

9.6.5.4.2. Growth Prospects

9.6.5.5. Taiwan

9.6.5.5.1. Market Trends and Opportunities

9.6.5.5.2. Growth Prospects

9.6.5.6. Thailand

9.6.5.6.1. Market Trends and Opportunities

9.6.5.6.2. Growth Prospects

9.6.5.7. Indonesia

9.6.5.7.1. Market Trends and Opportunities

9.6.5.7.2. Growth Prospects

9.6.5.8. Others

9.6.5.8.1. Market Trends and Opportunities

9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. BioLife Plasma Services 

11.2. Grifols International S.A. 

11.3. Biotest 

11.4. CSL Ltd. 

11.5. Bio Products Laboratory Ltd. 

11.6. China Biologic Products Inc. 

11.7. Kedrion S.p.A. 

11.8. Octapharma 


BioLife Plasma Services 

Grifols International S.A. 

Biotest 

CSL Ltd. 

Bio Products Laboratory Ltd. 

China Biologic Products Inc. 

Kedrion S.p.A. 

Octapharma